FOLFIRI plus cetuximab—preferred first-line treatment for mCRC

被引：0
|
作者：
Lisa Hutchinson
机构：
来源：
Nature Reviews Clinical Oncology | 2014年 / 11卷 / 10期
关键词：
D O I：
10.1038/nrclinonc.2014.141
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：560 / 560
相关论文
共 50 条
  • [1] Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal CA.
    Rougier, P
    Raoul, JL
    Van Laethem, JL
    Peeters, M
    Husseini, F
    Brezault, C
    Cals, L
    Vedovato, JC
    Mueser, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
  • [2] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [3] The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri
    Van Cutsem, E.
    Lang, I
    D'haens, G.
    Moiseyenko, V
    Zaluski, J.
    Koehne, C.
    Folprecht, G.
    Tejpar, S.
    Shparyk, Y.
    Schlichting, M.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 18
  • [4] CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Bodoky, G.
    Kyung Roh, J.
    Folprecht, G.
    Park, Y. S.
    Van Laethem, J. L.
    Raoul, J. L.
    Ciardiello, F.
    Lebrun, P.
    Rougier, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 235
  • [5] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] IMPACT ON QUALITY OF LIFE OF CETUXIMAB PLUS FOLFIRI IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE CRYSTAL TRIAL
    Lang, I
    Aleknaviciene, B.
    Zolotukhin, S.
    Komissarenko, V
    Garcia-Alfonso, P.
    Jurga, L.
    Moiseyenko, V
    Filipczyk-Cisarz, E.
    Zubel, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 24
  • [7] Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Oliner, K. S.
    Demonty, G.
    Koehne, C. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S375 - S376
  • [8] THE COST STUDY OF CETUXIMAB AND PANITUMUMAB IN THE FIRST-LINE TREATMENT OF MCRC IN THE CZECH REPUBLIC
    Hradecka, I
    Rihova, B.
    Demlova, R.
    VALUE IN HEALTH, 2017, 20 (09) : A426 - A426
  • [9] Tumor response as important parameter during first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Demonty, G.
    Koehne, C. -H
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 73 - 73
  • [10] Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345